Oct 29, 4:05 PM ET
ResMed Inc. reported first-quarter fiscal year 2027 revenue of $1.4 billion, representing a 6% increase compared to the prior-year period. GAAP diluted earnings per share rose 23% to $2.92, while the board declared a quarterly cash dividend of $0.66 per share.
- Q1 revenue increased 6% to $1.4 billion, or 7% on a core constant currency basis.
- GAAP diluted earnings per share grew 23% to $2.92, and non-GAAP diluted EPS rose 14% to $2.91.
- The board of directors declared a quarterly cash dividend of $0.66 per share, payable on December 17, 2026, with a record date of November 12, 2026.
- The company returned more than $1.0 billion to shareholders through share repurchases and dividends during the quarter.
Read the filing on SEC.gov ↗
Aug 17, 4:30 PM ET
ResMed dismissed KPMG as its independent auditor on August 13, 2026, and appointed PricewaterhouseCoopers for the fiscal year ending June 30, 2027, subject to PwC's client acceptance procedures. The filing also reports that director Ron Taylor will not stand for reelection and will retire at the November 18, 2026 annual meeting, with Carol Burt named lead director effective November 15, 2026.
- KPMG's reports on the fiscal 2026 and 2025 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing reports no disagreements or reportable events.
- PwC appointed on August 13, 2026, following a competitive review by the Audit Committee, subject to completion of its standard client acceptance procedures.
- Ron Taylor, a director since 2005 and lead director since 2013, is retiring at the 2026 Annual Meeting on November 18, 2026, and his retirement is not due to any disagreement with the company.
- Carol Burt, a Board member since 2013 who chairs the Nominating and Governance Committee, becomes lead director on November 15, 2026.
Read the filing on SEC.gov ↗
Aug 6, 4:05 PM ET
ResMed reported fiscal fourth-quarter 2026 revenue of $1.46 billion, up 9% from a year earlier, and GAAP diluted earnings per share of $2.64, up 2%. Its board also declared a 10% dividend increase to $0.66 per share, with an ex-dividend date of August 19, 2026, which matters to shareholders receiving the payout.
- Q4 revenue $1.46 billion, up 9% (8% in constant currency); GAAP diluted EPS $2.64, up 2%
- Non-GAAP diluted EPS $2.95, up 16%; GAAP results include $42 million in Astral field safety notification expenses
- Quarterly dividend of $0.66 per share, record date August 20, 2026, payable September 24, 2026
- Company guides to more than $1.85 billion returned to shareholders through buybacks and dividends in fiscal 2027
Read the filing on SEC.gov ↗
Jul 7, 5:24 PM ET
ResMed agreed on June 30, 2026 to sell its MatrixCare business to private equity firm Frazier Healthcare Partners for $490 million in cash, subject to closing adjustments. The company plans to use the proceeds to return capital to shareholders, including an accelerated share repurchase, and for general corporate purposes. The filing reiterates ResMed's fiscal 2026 outlook and says the full fiscal 2027 outlook will be given on August 6, 2026.
- Buyer is Frazier Healthcare Partners; price is $490 million all-cash, subject to certain closing adjustments.
- Deal is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions.
- MatrixCare had approximately $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026, based on preliminary results.
- Recently completed Noctrix acquisition is expected to add about $30 million of fiscal 2027 revenue and reduce non-GAAP diluted EPS by about $0.20.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
